CRISPR Nuclease Portfolio Expanded with Addition of Eureca-V

CRISPR protein, Eureca-V™ Nuclease is the most recent addition to our catalog. It is based on the proprietary MAD7® nuclease developed by Inscripta®. Aldevron and Inscripta have partnered to make this protein broadly available to the therapeutic, diagnostic, and agricultural research markets.

Mechanism of Action & Benefits

Like all standard Aldevron nucleases in our catalog, Eureca-V has a simple construct design of:

Where sNLS is a standard SV40 Large T-antigen Nuclear Localization Signal. Eureca-V does not contain any affinity tags, nor are any used during the manufacture of this product.

Eureca-V is categorized as a Class 2, Type V CRISPR-Cas nuclease. It shares key features common to this family of CRISPR nucleases, including:

• Targets broad array of T-rich PAM domains (YTTV preferred, TTTN functions)
• Requires a single crRNA to cut target DNA sequence
• Staggered double-strand break at cut site creates 5’ overhangs

Resources

• BROCHURE: Advancing CRISPR-based Therapeutic Development
• WHITEPAPER: Next-Generation CRISPR Approaches: Explore Strategies to Advance Therapeutic Programs Supporting Current Regulatory Guidance
• WHITEPAPER: Expectations on the Pathway to GMP for Gene-Modified Cell Therapies
• CASE STUDY: Enabling Novel CRISPR-Cas9 Delivery: A Case Study Supporting Innovative Genomics Insititute

Ordering Information

*Licensed from Inscripta®

Request Custom Manufacturing Information

*Licensed from Inscripta®